This site is intended for US-based Health Care Professionals only.
Learn more about ORENCIA for adults with active psoriatic arthritis (PsA)
Is it time to consider another treatment option for your patients with active psoriatic arthritis?
ORENCIA Is Indicated for Adults With Active Psoriatic Arthritis (PsA)
ORENCIA was studied in 2 clinical trials in patients with active psoriatic arthritis.
for active PsA?
for active PsA?
ORENCIA offers the flexibility of subcutaneous (SC) or intravenous (IV) administration for adult patients with active PsA
ORENCIA IV is a 30-minute infusion
4-week dosing schedule
Following the starter doses, ORENCIA IV is
maintained with a regular
*Actual day of dosing may vary based on patient scheduling.
Adult weight-based dosing
For injection: 250 mg white lyophilized powder in a single-dose vial (one may use less than the full contents of the vials or use more than one vial).
Immediately discard any unused portion
in the vials.
If there are any product defects, call
to receive a new vial.
Selected Important
Safety Information
Increased Risk of Infection with Concomitant Use with TNF Antagonists, Other Biologic RA/PsA Therapy, or JAK Inhibitors:
Concurrent therapy with ORENCIA and a TNF antagonist is not recommended. In controlled clinical trials, adult RA patients receiving concomitant intravenous ORENCIA and TNF antagonist therapy experienced more infections
ORENCIA SC allows patients once-weekly
self-injection at home
Recommendations for subcutaneous administration with ORENCIA prefilled syringe
-
ORENCIA prefilled syringes are intended for:
- Subcutaneous use only and are not intended for intravenous infusion
- Use under the guidance of a physician or healthcare practitioner
- After proper training in subcutaneous injection technique, a patient or the patient’s caregiver may administer a subcutaneous injection of ORENCIA (prefilled syringe) if a healthcare practitioner determines that it is appropriate
- Instruct patients and/or caregivers to follow the directions provided in the Instructions for Use for additional details on administration. Specifically instruct them to inject the full amount (which provides the proper dose of ORENCIA), rotate injection sites, and to avoid injections into areas where the skin is tender, bruised, red, or hard
- Visually inspect for particulate matter and discoloration prior to administration. Do not use ORENCIA prefilled syringes exhibiting particulate matter or discoloration. ORENCIA should be clear to slightly opalescent and colorless to pale yellow
ORENCIA prefilled syringes may be initiated without the need for an IV loading dose
125-mg SC injection is supplied in a prefilled syringe with BD UltraSafe Passive™ needle guard for once-weekly use.
For patients switching from ORENCIA intravenous infusions to subcutaneous administration, administer the first subcutaneous dose instead of the next scheduled intravenous dose.
Device highlights*
*125-mg syringe shown.
(29-gauge needle)
ORENCIA ClickJect™ Autoinjector—automatically
delivers the full dose
with one push of a button
125-mg SC injection is supplied in the ClickJect™ Autoinjector for once-weekly use.
Recommendations for subcutaneous administration
-
ORENCIA ClickJect autoinjectors are intended for:
- Subcutaneous use only and are not intended for intravenous infusion
- Use under the guidance of a physician or healthcare practitioner
- After proper training in subcutaneous injection technique, a patient or the patient’s caregiver may administer a subcutaneous injection of ORENCIA (ClickJect™ autoinjector) if a physician/healthcare practitioner determines that it is appropriate
- Instruct patients and/or caregivers to follow the directions provided in the Instructions for Use for additional details on administration. Specifically instruct patients to inject the full amount (which provides the proper dose of ORENCIA), rotate injection sites, and to avoid injections into areas where the skin is tender, bruised, red, or hard
- Visually inspect for particulate matter and discoloration prior to administration. Do not use ORENCIA ClickJect autoinjectors exhibiting particulate matter or discoloration. ORENCIA should be clear to slightly opalescent and colorless to pale yellow
ORENCIA ClickJect™ autoinjectors may be initiated without the need for an IV loading dose
125-mg SC injection is supplied in a prefilled syringe with BD UltraSafe Passive™ Needle Guard for once-weekly use.
For patients switching from ORENCIA intravenous infusions to subcutaneous administration, administer the first subcutaneous dose instead of the next scheduled intravenous dose.
Device highlights
Accurate dose self-injection comes with push-button operation and confirmation that the full dose has been injected.